<DOC>
	<DOCNO>NCT01808638</DOCNO>
	<brief_summary>The purpose study evaluate new treatment strategy advance pancreatic cancer disease combine new investigational medicinal product Atu027 standard chemotherapeutic gemcitabine . This combination aim enhance gemcitabine´s anti-tumor activity Atu027 . The objective clinical trial evaluate safety activity two Atu027 schedule combination standard gemcitabine treatment patient advance metastatic pancreatic adenocarcinoma .</brief_summary>
	<brief_title>Atu027 Plus Gemcitabine Advanced Metastatic Pancreatic Cancer ( Atu027-I-02 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Pancreatic Ductal</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Leadin safety period : Subjects age 18 84 year Histologically cytologically confirm advanced refractory cholangiocellular carcinoma , biliary tract cancer , nonsmallcell lung carcinoma , duodenal cancer , soft tissue sarcoma , ovarian carcinoma , another nonpancreatic cancer disease indicate gemcitabine treatment determine investigator Subjects previously receive chemotherapy standard curative palliative care available , effective , unlikely effective No option surgical resection radiation curative intent Eastern Cooperative Oncology Group ( ECOG ) performance status assessment 0 2 Life expectancy least 3 month No interstitial pneumonia extensive symptomatic interstitial fibrosis lung Alanine aminotransferase ( ALT ) ≤3.0 x upper limit normal ( ULN ; ≤5 x ULN subject liver metastasis ) Aspartate aminotransferase ( AST ) ≤3.0 x ULN ( ≤5 x ULN subject liver involvement cancer ) Total bilirubin ≤2.0 x ULN ( liver metastasis &lt; 5 x ULN ) Serum creatinine ≤1.5 x ULN Adequate bone marrow function : subject absolute granulocyte count least 1,500 ( x 10e6/L ) platelet count 100,000 ( x 10e6/L ) prior initiation cycle . Prothrombin timeinternational normalize ratio/partial thromboplastin time ( PTINR/PTT ) &lt; 1.5 x ULN ( subject therapeutically anticoagulated agent coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist ) . Lowdose aspirin permit ( ≤100 mg daily ) . Women childbearing potential must negative urine pregnancy test baseline . Women childbearing potential men must willing use highly effective contraceptive method course study 6 month . Subjects must willing able ( opinion investigator ) understand subject information inform consent form comply study protocol procedure . Subjects must willing able give write informed consent . Main part : Subjects age 18 84 year Subjects locally advanced metastatic pancreatic adenocarcinoma stage III/IV indicate gemcitabine treatment determine investigator No option surgical resection radiation curative intent Histological cytological documentation nonhematologic , malignant solid tumor At least one measurable lesion evaluable disease , per Response Evaluation Criteria In Solid Tumors ( RECIST ) Version 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status assessment 0 2 Life expectancy least 3 month No interstitial pneumonia extensive symptomatic interstitial fibrosis lung Alanine aminotransferase ( ALT ) &lt; =3.0 x upper limit normal ( ULN ; &lt; =5 x ULN subject liver metastasis ) Aspartate aminotransferase ( AST ) &lt; =3.0 x ULN ( &lt; =5 x ULN subject liver involvement cancer ) Total bilirubin &lt; =2.0 x ULN ( liver metastasis &lt; =5 x ULN ) Serum creatinine &lt; =1.5 x ULN Adequate bone marrow function : subject absolute granulocyte count least 1,500 ( x 10e6/L ) platelet count 100,000 ( x 10e6/L ) prior initiation cycle . Prothrombin timeinternational normalize ratio/partial thromboplastin time ( PT INR/PTT ) &lt; 1.5 x ULN ( subject therapeutically anticoagulated agent coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist ) . Lowdose aspirin permit ( ≤100 mg daily ) . Women childbearing potential must negative urine pregnancy test baseline . Women childbearing potential men must willing use highly effective contraceptive method course study 6 month . Subjects must willing able ( opinion investigator ) understand subject information inform consent form comply study protocol procedure . Subjects must willing able give write informed consent . Leadin safety period : History cardiac disease ; congestive heart failure &gt; New York Heart Association ( NYHA ) functional classification system Class II ; active coronary artery disease , myocardial infarction within 6 month prior study entry ; new onset angina within 3 month prior study entry unstable angina , ventricular cardiac arrhythmia require antiarrhythmic therapy Poorly control diabetes define hemoglobin A1c ( HbA1c ) &gt; =7 % Poorly control hypertension , define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management Poorly control seizure disorder Subjects undergoing renal dialysis Known hypersensitivity study drug active substance excipients preparation Pregnant breast feed Known hepatitis B C human immunodeficiency virus ( HIV ) infection ( document subject 's record Previous participation study Current previous ( within 30 day enrolment ) treatment another investigational drug participation another clinical study . Subject relative , staff directly report investigator . Subject employee sponsor . Subject commit official judicial order . Any reason investigator considers make subject unsuitable participate Main part : History cardiac disease ; congestive heart failure &gt; New York Heart Association ( NYHA ) functional classification system Class II ; active coronary artery disease , myocardial infarction within 6 month prior study entry ; new onset angina within 3 month prior study entry unstable angina , ventricular cardiac arrhythmia require antiarrhythmic therapy Poorly control diabetes define hemoglobin A1c ( HbA1c ) &gt; =8 % Poorly control hypertension , define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management Poorly control seizure disorder Subjects undergoing renal dialysis Anticancer chemotherapy immunotherapy study first study treatment . Subjects recurrent disease adjuvant treatment progressionfree least 6 month . Radiotherapy target lesion study study start Known hypersensitivity study drug active substance excipients preparation Pregnant breast feed Known hepatitis B C human immunodeficiency virus ( HIV ) infection ( document subject 's record Previous participation study Current previous ( within 30 day enrolment ) treatment another investigational drug participation another clinical study . Subject relative , staff directly report investigator . Subject employee sponsor . Subject commit official judicial order . Any reason investigator considers make subject unsuitable participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Pancreas</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Atu027</keyword>
</DOC>